Compare Nuscale Power Corporation (SMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs BIO-TECHNE Corp — how do they compare? Nuscale Power Corporation trades at $7.45 (market cap $3.15B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 3.6× Nuscale Power Corporation's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and BIO-TECHNE Corp for 63 Days on average.
| SMR | TECH | |
|---|---|---|
Market Cap | $3.15B | $11.37B |
Volume | 38,437,205 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $53.43 | $72.61 |
52-Week Low | $7.32 | $43.31 |
Typical Hold Time | 29 Days | 63 Days |
Enterprise Value | $2.08B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $7.67, down 4.42% today, amid bearish technical signals and negative profitability metrics. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with analyst consensus showing a mixed 50% buy rating but a $11.25 price target. Recent news highlights ongoing legal investigations and competitive pressures in the nuclear energy sector.
The outlook remains challenging with significant operational losses and cash burn, though analyst targets suggest potential upside. Key risks include execution on commercialization, dilution concerns, and intense SMR competition. The stock's future hinges on converting its $1.1 billion cash position into revenue-generating projects.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
